CD276 and neoplasm: Targeting of B7-H3 could also overcome resistance to the standard anti-GD2 immunotherapy in NB children with GD2-negative or GD2-low tumor variants, who represent a relevant percentage (about 12%) of newly diagnosed patients [23,24].